MedImmune 4Q Revenues: $492 million (+6%) 4Q Loss: $22 million (earnings were $50.5 million 4Q2004) FY Revenues: $1.2 billion (+9%) FY Loss: $17 million (loss of $3.8 million FY2004) Comments: Worldwide sales of Synagis grew 13% to $1.1 billion for the year. Sales of FluMist decreased 56% for the year to $21 million and decreased 61% to $8 million for the quarter. R&D spending decreased 2% for the quarter to $117 million, and increased 27% for the year to $383 million....